Table 3.
Overall and progression-free survival
| Surgery arm | Chemotherapy arm | |
|---|---|---|
| Overall survival | ||
| Median (95% CI) | 2.1 years (1.8–4.2) | 3.67 years (2.3–4.7) |
| 5-year survival rate (95% CI) | 32.6% (23.0–42.1) | 38.0% (28.4–47.6) |
| 10-year survival rate (95% CI) | 13.8% (6.1–21.6) | 13.1% (5.6–20.6) |
| Hazard ratio (95% CI) | 0.88 (0.65–1.19) | |
| Progression-free survival | ||
| Median (95% CI) | 1.6 years (1.2–2.4) | 2.1 years (1.4–3.6) |
| 5-year event-free rate (95% CI) | 26.4% (17.5–35.4) | 31.7% (22.5–40.9) |
| 10-year event-free rate (95% CI) | 8.5% (2.0–15.0) | 10.8% (3.8–17.9) |
| Hazard ratio (95% CI) | Reference group | 081 (0.60–1.09) |
| Progression-free survival (including second cancer as event) | ||
| Median (95% CI) | 1.4 years (1.1–2.1) | 1.8 years (1.3–3.0) |
| 5-year event-free rate (95% CI) | 24.1% (15.4–32.9) | 26.8% (18.1–35.5) |
| 10-year event-free rate (95% CI) | 6.7% (1.2–12.1) | 8.6% (2.3–14.9) |
| Hazard ratio (95% CI) | Reference group | 0.83 (0.62–1.12) |
CI, confidence interval.